Addus HomeCare (ADUS) Competitors

$90.98 -1.43 (-1.55%)

Closing price 04:00 PM Eastern

Extended Trading

$90.98 +0.00 (+0.01%)

As of 05:30 PM Eastern

ADUS vs. CELC, HIMS, PACS, CAI, and RDNT

Should you buy Addus HomeCare stock or one of its competitors? MarketBeat compares Addus HomeCare with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Addus HomeCare include Celcuity (CELC), Hims & Hers Health (HIMS), PACS Group (PACS), Caris Life Sciences (CAI), and RadNet (RDNT). These companies are all part of the "healthcare" industry.

How does Addus HomeCare compare to Celcuity?

Celcuity (NASDAQ:CELC) and Addus HomeCare (NASDAQ:ADUS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, media sentiment, profitability, valuation and analyst recommendations.

In the previous week, Celcuity had 5 more articles in the media than Addus HomeCare. MarketBeat recorded 12 mentions for Celcuity and 7 mentions for Addus HomeCare. Addus HomeCare's average media sentiment score of 0.78 beat Celcuity's score of 0.65 indicating that Addus HomeCare is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
Addus HomeCare	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

63.3% of Celcuity shares are owned by institutional investors. Comparatively, 95.4% of Addus HomeCare shares are owned by institutional investors. 13.3% of Celcuity shares are owned by company insiders. Comparatively, 4.5% of Addus HomeCare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Celcuity currently has a consensus price target of $140.20, suggesting a potential upside of 1.83%. Addus HomeCare has a consensus price target of $131.22, suggesting a potential upside of 44.23%. Given Addus HomeCare's higher possible upside, analysts clearly believe Addus HomeCare is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Addus HomeCare	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73

Addus HomeCare has a net margin of 6.89% compared to Celcuity's net margin of 0.00%. Addus HomeCare's return on equity of 9.80% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-203.17%	-52.68%
Addus HomeCare	6.89%	9.80%	7.34%

Celcuity has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market. Comparatively, Addus HomeCare has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

Addus HomeCare has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$3.79	N/A
Addus HomeCare	$1.42B	1.19	$95.91M	$5.41	16.82

Summary

Addus HomeCare beats Celcuity on 12 of the 16 factors compared between the two stocks.

How does Addus HomeCare compare to Hims & Hers Health?

Hims & Hers Health (NYSE:HIMS) and Addus HomeCare (NASDAQ:ADUS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Hims & Hers Health has higher revenue and earnings than Addus HomeCare. Hims & Hers Health is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.37B	2.41	$128.37M	-$0.09	N/A
Addus HomeCare	$1.42B	1.19	$95.91M	$5.41	16.82

In the previous week, Hims & Hers Health had 68 more articles in the media than Addus HomeCare. MarketBeat recorded 75 mentions for Hims & Hers Health and 7 mentions for Addus HomeCare. Addus HomeCare's average media sentiment score of 0.78 beat Hims & Hers Health's score of -0.01 indicating that Addus HomeCare is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hims & Hers Health	16 Very Positive mention(s)	10 Positive mention(s)	11 Neutral mention(s)	24 Negative mention(s)	6 Very Negative mention(s)	Neutral
Addus HomeCare	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

63.5% of Hims & Hers Health shares are owned by institutional investors. Comparatively, 95.4% of Addus HomeCare shares are owned by institutional investors. 11.8% of Hims & Hers Health shares are owned by company insiders. Comparatively, 4.5% of Addus HomeCare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Addus HomeCare has a net margin of 6.89% compared to Hims & Hers Health's net margin of -0.56%. Addus HomeCare's return on equity of 9.80% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	-0.56%	6.10%	1.52%
Addus HomeCare	6.89%	9.80%	7.34%

Hims & Hers Health currently has a consensus price target of $29.50, suggesting a potential upside of 17.70%. Addus HomeCare has a consensus price target of $131.22, suggesting a potential upside of 44.23%. Given Addus HomeCare's stronger consensus rating and higher probable upside, analysts clearly believe Addus HomeCare is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	2 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.12
Addus HomeCare	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73

Hims & Hers Health has a beta of 2.43, indicating that its stock price is 143% more volatile than the broader market. Comparatively, Addus HomeCare has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market.

Summary

Addus HomeCare beats Hims & Hers Health on 11 of the 17 factors compared between the two stocks.

How does Addus HomeCare compare to PACS Group?

PACS Group (NYSE:PACS) and Addus HomeCare (NASDAQ:ADUS) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

PACS Group has higher revenue and earnings than Addus HomeCare. Addus HomeCare is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PACS Group	$5.29B	1.12	$191.54M	$1.56	24.06
Addus HomeCare	$1.42B	1.19	$95.91M	$5.41	16.82

In the previous week, PACS Group had 5 more articles in the media than Addus HomeCare. MarketBeat recorded 12 mentions for PACS Group and 7 mentions for Addus HomeCare. PACS Group's average media sentiment score of 0.98 beat Addus HomeCare's score of 0.78 indicating that PACS Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PACS Group	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Addus HomeCare	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

95.4% of Addus HomeCare shares are owned by institutional investors. 70.1% of PACS Group shares are owned by company insiders. Comparatively, 4.5% of Addus HomeCare shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Addus HomeCare has a net margin of 6.89% compared to PACS Group's net margin of 4.49%. PACS Group's return on equity of 26.47% beat Addus HomeCare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PACS Group	4.49%	26.47%	4.36%
Addus HomeCare	6.89%	9.80%	7.34%

PACS Group currently has a consensus price target of $45.60, suggesting a potential upside of 21.48%. Addus HomeCare has a consensus price target of $131.22, suggesting a potential upside of 44.23%. Given Addus HomeCare's higher probable upside, analysts clearly believe Addus HomeCare is more favorable than PACS Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PACS Group	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
Addus HomeCare	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73

PACS Group has a beta of -0.03, indicating that its stock price is 103% less volatile than the broader market. Comparatively, Addus HomeCare has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market.

Summary

PACS Group and Addus HomeCare tied by winning 8 of the 16 factors compared between the two stocks.

How does Addus HomeCare compare to Caris Life Sciences?

Addus HomeCare (NASDAQ:ADUS) and Caris Life Sciences (NASDAQ:CAI) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Addus HomeCare has a net margin of 6.89% compared to Caris Life Sciences' net margin of 3.75%. Caris Life Sciences' return on equity of 98.28% beat Addus HomeCare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addus HomeCare	6.89%	9.80%	7.34%
Caris Life Sciences	3.75%	98.28%	48.87%

Addus HomeCare presently has a consensus price target of $131.22, suggesting a potential upside of 44.23%. Caris Life Sciences has a consensus price target of $27.56, suggesting a potential upside of 89.39%. Given Caris Life Sciences' higher possible upside, analysts clearly believe Caris Life Sciences is more favorable than Addus HomeCare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addus HomeCare	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
Caris Life Sciences	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Addus HomeCare has higher revenue and earnings than Caris Life Sciences. Caris Life Sciences is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addus HomeCare	$1.42B	1.19	$95.91M	$5.41	16.82
Caris Life Sciences	$812.03M	5.07	-$68.09M	-$7.61	N/A

95.4% of Addus HomeCare shares are held by institutional investors. 4.5% of Addus HomeCare shares are held by insiders. Comparatively, 7.8% of Caris Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Caris Life Sciences had 6 more articles in the media than Addus HomeCare. MarketBeat recorded 13 mentions for Caris Life Sciences and 7 mentions for Addus HomeCare. Addus HomeCare's average media sentiment score of 0.78 beat Caris Life Sciences' score of 0.09 indicating that Addus HomeCare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Addus HomeCare	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Caris Life Sciences	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Addus HomeCare beats Caris Life Sciences on 10 of the 16 factors compared between the two stocks.

How does Addus HomeCare compare to RadNet?

Addus HomeCare (NASDAQ:ADUS) and RadNet (NASDAQ:RDNT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Addus HomeCare has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market. Comparatively, RadNet has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market.

Addus HomeCare has a net margin of 6.89% compared to RadNet's net margin of -0.66%. Addus HomeCare's return on equity of 9.80% beat RadNet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Addus HomeCare	6.89%	9.80%	7.34%
RadNet	-0.66%	2.77%	0.97%

Addus HomeCare presently has a consensus price target of $131.22, suggesting a potential upside of 44.23%. RadNet has a consensus price target of $88.14, suggesting a potential upside of 68.24%. Given RadNet's stronger consensus rating and higher possible upside, analysts clearly believe RadNet is more favorable than Addus HomeCare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addus HomeCare	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
RadNet	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Addus HomeCare has higher earnings, but lower revenue than RadNet. RadNet is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addus HomeCare	$1.42B	1.19	$95.91M	$5.41	16.82
RadNet	$2.04B	2.02	-$18.65M	-$0.18	N/A

95.4% of Addus HomeCare shares are held by institutional investors. Comparatively, 77.9% of RadNet shares are held by institutional investors. 4.5% of Addus HomeCare shares are held by insiders. Comparatively, 5.6% of RadNet shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, RadNet had 6 more articles in the media than Addus HomeCare. MarketBeat recorded 13 mentions for RadNet and 7 mentions for Addus HomeCare. Addus HomeCare's average media sentiment score of 0.78 beat RadNet's score of 0.29 indicating that Addus HomeCare is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Addus HomeCare	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
RadNet	2 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Addus HomeCare beats RadNet on 9 of the 17 factors compared between the two stocks.

Get Addus HomeCare News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADUS vs. The Competition

Export

Metric	Addus HomeCare	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.70B	$5.51B	$6.23B	$12.27B
Dividend Yield	N/A	1.56%	2.80%	5.35%
P/E Ratio	16.82	33.92	20.14	25.23
Price / Sales	1.19	21.68	542.44	73.19
Price / Cash	14.55	16.43	43.26	56.33
Price / Book	1.52	3.14	9.81	6.90
Net Income	$95.91M	$218.81M	$3.56B	$333.88M
7 Day Performance	-8.63%	-1.05%	0.33%	0.04%
1 Month Performance	-2.51%	2.68%	-0.98%	1.74%
1 Year Performance	-17.22%	15.02%	36.19%	32.64%

Addus HomeCare Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADUS Addus HomeCare	4.7052 of 5 stars	$90.98 -1.5%	$131.22 +44.2%	-14.6%	$1.70B	$1.42B	16.82	50,659	Analyst Forecast
CELC Celcuity	1.7527 of 5 stars	$141.54 -2.4%	$134.50 -5.0%	+1,140.5%	$6.84B	N/A	N/A	40	News Coverage Earnings Report Analyst Forecast Gap Down
HIMS Hims & Hers Health	3.8159 of 5 stars	$26.25 -3.7%	$32.53 +23.9%	-60.8%	$6.03B	$2.35B	51.86	2,442	Trending News Earnings Report Analyst Forecast Options Volume
PACS PACS Group	3.9261 of 5 stars	$32.58 +0.2%	$44.40 +36.3%	+264.8%	$5.16B	$5.29B	26.68	47,455	Earnings Report Analyst Forecast Gap Up
CAI Caris Life Sciences	4.3105 of 5 stars	$18.15 -2.9%	$28.86 +59.0%	N/A	$5.14B	$812.03M	N/A	1,846	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADUS) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Addus HomeCare (ADUS) Competitors

ADUS vs. CELC, HIMS, PACS, CAI, and RDNT

How does Addus HomeCare compare to Celcuity?

Summary

How does Addus HomeCare compare to Hims & Hers Health?

Summary

How does Addus HomeCare compare to PACS Group?

Summary

How does Addus HomeCare compare to Caris Life Sciences?

Summary

How does Addus HomeCare compare to RadNet?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADUS vs. The Competition

Addus HomeCare Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Addus HomeCare (ADUS) Competitors

ADUS vs. CELC, HIMS, PACS, CAI, and RDNT

How does Addus HomeCare compare to Celcuity?

Does the media refer more to CELC or ADUS?

Do institutionals and insiders have more ownership in CELC or ADUS?

Do analysts prefer CELC or ADUS?

Is CELC or ADUS more profitable?

Which has more volatility & risk, CELC or ADUS?

Which has higher valuation and earnings, CELC or ADUS?

Summary

How does Addus HomeCare compare to Hims & Hers Health?

Which has stronger earnings and valuation, HIMS or ADUS?

Does the media prefer HIMS or ADUS?

Do insiders & institutionals have more ownership in HIMS or ADUS?

Is HIMS or ADUS more profitable?

Do analysts prefer HIMS or ADUS?

Which has more risk & volatility, HIMS or ADUS?

Summary

How does Addus HomeCare compare to PACS Group?

Which has stronger earnings and valuation, PACS or ADUS?

Does the media prefer PACS or ADUS?

Do insiders & institutionals have more ownership in PACS or ADUS?

Is PACS or ADUS more profitable?

Do analysts prefer PACS or ADUS?

Which has more risk & volatility, PACS or ADUS?

Summary

How does Addus HomeCare compare to Caris Life Sciences?

Is ADUS or CAI more profitable?

Do analysts recommend ADUS or CAI?

Which has preferable earnings and valuation, ADUS or CAI?

Do institutionals & insiders have more ownership in ADUS or CAI?

Does the media favor ADUS or CAI?

Summary

How does Addus HomeCare compare to RadNet?

Which has more risk & volatility, ADUS or RDNT?

Is ADUS or RDNT more profitable?

Do analysts recommend ADUS or RDNT?

Which has preferable earnings and valuation, ADUS or RDNT?

Do institutionals & insiders have more ownership in ADUS or RDNT?

Does the media favor ADUS or RDNT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADUS vs. The Competition

Addus HomeCare Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools